Luthra P, et al. - In patients with chronic idiopathic constipation, researchers conducted this systematic review and network meta-analysis to test the effectiveness of drugs (osmotic or stimulant laxatives, elobixibat, linaclotide, lubiprostone, mizagliflozin, naronapride, plecanatide, prucalopride, tegaserod, tenapanor, or velusetrag). Thirty-three eligible randomised controlled trials of drugs were identified, comprising 17,214 patients. According to findings, nearly all drugs tested were superior to placebo, either because they failed to achieve three or more complete spontaneous bowel movements (CSBMs) per week or because they failed to achieve one or more CSBMs per week over baseline. While diphenyl methane laxatives ranked first at 4 weeks, these trials may have included patients with milder symptoms. Prucalopride ranked first at 12 weeks, and many of the included studies enrolled patients who had not previously responded to laxatives, indicating that this medicine is likely to be the most successful for chronic idiopathic constipation patients. Nevertheless, the long-term comparative effectiveness of these medications is uncertain because the duration of treatment in most trials was 4–12 weeks.